REFERENCES
- Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44: 1009–34.
- Lemaire-Hurtel AS, Gras-Champel V, Hary L, Masmoudi K, Massy Z, Andréjak M. Recommended dosage adaptation based on renal function is not always sufficient to avoid beta-lactam antibiotics side effects. Nephrol Ther 2009; 5: 144–8.
- Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010; 36: 332–9.
- Verdier MC, Tribut O, Tattevin P, Le Tulzo Y, Michelet C, Bentué-Ferrer D. Simultaneous determination of twelve beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. Application to therapeutic drug monitoring. Antimicrob Agents Chemother. 2011; 55: 4873–9
- Chow KM, Hui AC, Szeto CC. Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis 2005; 24: 649–53.
- Verdier MC, Tribut O, Tattevin P, Michelet C, Allain H, Bentué-Ferrer D. Beta-lactams: Therapeutic Drug Monitoring versus dosing adaptation with creatinine level. Fund Clin Pharmacol 2004; 18: 266.
- Tattevin P, Tribut O, Arvieux C, Dupont M, Flicoteaux R, Desbordes L, et al. Use of high-performance liquid chromatography (HPLC) to monitor beta-lactam plasma concentrations during the treatment of endocarditis. Clin Microbiol Infect 2005; 11: 76–9.
- Visser LG, Amouts P, van Furth R, Mattie H, van den Broek PJ. Clinical pharmacokinetics of continuous intravenous administration of penicillins. Clin Infect Dis 1993; 17: 491–5.
- Pullen J, Stolk LM, Nieman FH, Degraeuwe PL, van Tiel FH, Zimmermann U. Population pharmacokinetics and dosing of amoxicillin in (pre)term neonates. Ther Drug Monit 2006; 28: 226–31.
- Tattevin P, Tribut O, Polard E, Gouaillier F, Mercier M, Kervegant C, et al. Adverse events and beta-lactams trough plasma concentrations during the treatment of endocarditis. In 17th European Congress of Clinical Micro-biology and Infectious diseases, Munich, 31 March - 3 April 2007.
- Conil JM, Georges B, Lavit M, Murray JA, Sava J, Salim A, et al. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance. Int J Clin Pharmacol Ther 2007; 45: 529–38.
- Navas D, Caillon J, Batard E, Le Conte P, Kergueris MF, Moreau P, et al. Trough serum concentrations of beta-lactam antibiotics in cancer patients: inappropriateness of conventional schedules to pharmacokinetic/ pharmacodynamic properties of beta-lactams. Int J Antimicrob Agents 2006; 27: 102–7.
- Kasiakou SK, Lawrence KR, Choulis N, Falagas ME. Continuous ver-sus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmaco-dynamic parameters. Drugs 2005; 65: 2499–2511.
- Hughes DW, Frei CR, Maxwell PR, Green K, Patterson JE, Crawford GE, et al. Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus au-reus. Antimicrob Agents Chemother 2009; 53: 2014–19.
- Roberts JA, Lipman J, Blot S, Rello J. Better outcomes through con-tinuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care 2008; 14: 390–6
- Blondiaux N, Wallet F, Favory R, Onimus T, Nseir S, Courcol RJ, et al. Daily serum piperacillin monitoring is advisable in critically ill patients. Int J Antimicrob Agents 2010; 35: 500–3.